Experimental combo targets Tough-to-Treat colorectal cancer

NCT ID NCT06654037

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether combining two drugs—abemaciclib and 5-fluorouracil—is safe and tolerable for people with advanced colorectal cancer that has spread and stopped responding to standard treatments. About 39 participants will receive the combination to find the best dose and watch for side effects. The goal is to see if this approach can control the disease when other options have failed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

abemaciclib and 5-fluorouracil

What this could lead to

If this combination proves safe and effective, it could offer a new treatment option for patients with advanced colorectal cancer that has stopped responding to standard therapies.

What could go wrong

This is a very early (Phase 1) trial with only 39 participants, so the main goal is safety and dosing, not proof of benefit. The cancer is aggressive and heavily pre-treated, so even if safe, the combination may not shrink tumors or extend survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IV COLORECTAL CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Montefiore Medical Center - Moses Campus

    RECRUITING

    The Bronx, New York, 10467, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Montefiore Medical Center-Einstein Campus

    RECRUITING

    The Bronx, New York, 10461, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Montefiore Medical Center-Weiler Hospital

    RECRUITING

    The Bronx, New York, 10461, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    RECRUITING

    Orange, California, 92868, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    RECRUITING

    Irvine, California, 92612, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Cincinnati Cancer Center-UC Medical Center

    RECRUITING

    Cincinnati, Ohio, 45219, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Cincinnati Cancer Center-West Chester

    RECRUITING

    West Chester, Ohio, 45069, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pittsburgh Cancer Institute (UPCI)

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact

    Contact Phone: •••-•••-••••